Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2013OC003 Principal Investigator Lund, Troy
Phase NA
Age Group Both Scope Local
Secondary Protocol No. MT2013-06C
Title MT2013-06C : Treatment of graft Failure after HSCT
Objective - Incidence of sustained donor engraftment at day 42 post transplant - Incidence of transplant related mortality (TRM) at day 100 - Overall survival at day 100 and 1 year - Acute GVHD after this second transplant at day 100 and 6 months - Chronic GVHD after this second transplant at day 12 and 24 months
Description This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI)
Key Eligibility Patients with primary or secondary graft failure post transplant
Applicable Disease Sites Hodgkin's Lymphoma
Leukemia, not otherwise specified
Leukemia, other
Lymphoid Leukemia
Multiple Myeloma
Myeloid and Monocytic Leukemia
Non-Hodgkin's Lymphoma
Other Hematopoietic
Therapies Involved Blood and Marrow Transplant
Total Body Irradiation (TBI)
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Other
Contact Timothy Krepski Phone:612-273-2800